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IFN-Regulatory Factor 5 Gene Variants Interact with
the Class I MHC Locus in the Swedish Psoriasis
Population
Fabio O. Sa´nchez1, MV Prasad Linga Reddy2, Kazuko Sakuraba1,3, Mona Sta˚hle1 and
Marta E. Alarco´n-Riquelme2
Psoriasis is a multifactorial disease of the skin with significant comorbidities of the musculoskeletal and
cardiovascular system, which affects 2–3% of the Caucasian population. Failure to regulate prolonged T-helper
1-mediated inflammation is central to psoriasis and is a feature shared with other inflammatory diseases. IFNs
are important initiators/regulators of inflammation that among other things can affect the expression of the
main genetic determinant in psoriasis, namely HLA-C. Externally administered IFN-a, as in patients treated
for viral infections, and IFN-a produced by plasmacytoid dendritic cells is a known trigger of psoriasis. IFNg
is characteristically increased in psoriasis lesions. Expression of IFNs is controlled by factors such as
IFN-regulatory factor 5 (IRF5) whose polymorphic haplotypes were recently found to associate with increased
risk of systemic lupus erythematosus (SLE). The hypothesis underlying this study was that polymorphisms in the
IRF5 gene contribute to inadequate control of inflammation in psoriasis. This hypothesis was tested by
comparing the distribution of genotypes and haplotypes at IRF5 derived from genotyping single-nucleotide
polymorphisms (SNPs) rs2004640, rs2070197, rs10954213, and rs2280714 in psoriasis patients and population-
matched controls from the Stockholm Psoriasis Cohort. Polymorphisms at IRF5 did not associate with psoriasis
per se; however, an interaction with class I major histocompatibility complex (MHC) genes was found.
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INTRODUCTION
Psoriasis is a chronic inflammatory disease that affects 2–3%
of the Caucasian population, occurring equally in both males
and females. There are several clinical forms of the disease,
but most cases manifest as chronic plaque or as acute guttate
psoriasis (Christophers, 2001). Typically, skin lesions result
from keratinocyte hyperproliferation and altered differentia-
tion, and intense recruitment of inflammatory cells to the skin
along with changes in vascular proliferation and permeability
(Bowcock and Krueger, 2005).
Psoriasis is a multifactorial disease, which manifests in
genetically susceptible individuals after a presumed exposure
to environmental triggers. Known triggers include infections,
particularly streptococcal throat infections, which associate
with guttate psoriasis; stress; drugs such as b-blockers, non-
steroidal anti-inflammatory drugs, lithium, and so on;
smoking; treatment with IFN-a; and others (Bowcock and
Cookson, 2004). Several psoriasis susceptibility regions have
been described throughout the human genome, some of
which relate to other inflammatory diseases, particularly
atopic dermatitis (Bowcock and Cookson, 2004).
It is likely that common pathogenic mechanisms between
different inflammatory diseases exist; which is supported, not
only by sharing of common susceptibility loci, but also by
similarities in their underlying immune reactivity. For
example, the inflammatory processes in systemic lupus
erythematosus (SLE) and psoriasis are driven by a T-helper
1 immune response, while several psoriasis susceptibility loci
overlap with atopic eczema susceptibility loci (Calvani et al.,
2004; Lew et al., 2004; Lit et al., 2006). IFNs are important
players in shaping immune responses and appear to drive
type 1 inflammatory reactions in both diseases, particularly
IFN-a, which is known to trigger psoriasis (Funk et al., 1991;
Nestle et al., 2005) and also seems to contribute to SLE
(Ronnblom and Alm, 2003) as well as rheumatoid arthritis
(Cavanagh et al., 2005).
IFN-regulatory factor 5 (IRF5) is a factor that regulates IFN
expression and associates with high risk of SLE (Graham
et al., 2006; Honda et al., 2006; Tailor et al., 2006). An IRF5
haplotype was recently reported to associate with SLE
through two functional effects: introduction of a donor splice
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site leading to transcription from an alternative 50-untrans-
lated region (related to single-nucleotide polymorphism
(SNP) rs2004640) and overexpression of the gene (related
to SNPs rs2280714 and rs10954213) (Kozyrev et al., 2007).
We hypothesize that these two functional effects may play a
role in psoriasis, and therefore compared the distribution of
genotypes and haplotypes in IRF5 (SNPs rs2004640,
rs2070197, rs10954213, and rs2280714) between psoriasis
cases and healthy controls.
RESULTS
The level of HLA-Cw6 association with psoriasis in this
material was consistent with that reported in other studies by
us and other groups (odds ratio (OR)¼ 5.45, confidence
interval (CI)¼ 3.88–7.65, Po21016). The level of associa-
tion for guttate patients was also consistent with previous
findings (OR¼ 23.91, 95% CI¼14.55–39.3, Po2 1016).
Some characteristics of the patients studied here are
presented in Table 1, and a more detailed description of a
large part of this cohort is presented elsewhere (Mallbris
et al., 2005).
IRF5 polymorphisms do not associate per se with psoriasis
The allele, genotype, and haplotype distributions at IRF5, as
determined by genotyping SNPs rs2004640, rs2070197,
rs10954213, and rs2280714, did not differ between psoriasis
patients and population-matched controls (Table 2). Hard-
y–Weinberg expected genotype proportions were in equili-
brium for all markers tested. There was strong linkage
disequilibrium between SNPs rs2070197, rs10954213, and
rs2280714 (D040.9). Allele frequencies for rs2280714 were
consistent with those observed in the Utah residents with
ancestry from northern and western Europe, Centre d’Etude
du Polymorphisme Humaine (CEPH) population of the
HapMap project (Consortium’’, 2003). Frequencies of
the markers in healthy controls were in agreement with
those found in our previous studies (Graham et al., 2006;
Kozyrev et al., 2007). However, there was a decreased
frequency of individuals homozygous or heterozygous for the
hGTAT IRF5 haplotypes among patients (OR¼0.38, 95%
CI¼0.17–0.89, P¼0.025), marker order being the following:
rs2004640–rs2070197–rs10954213–rs2280714).
Interaction between IRF5 and HLA-G
Since IRF5 influences the expression of IFNs and these in turn
regulate the expression of several other potentially pathogenic
factors in psoriasis, such as class I major histocompatibility
complex (MHC) molecules, interaction between these factors
was tested at the genotypic level. A trend for interaction was
observed between rs16375 (a 14-bp deletion/deletion in exon
8 of HLA-G) and IRF5 rs2070197 under codominant and
recessive models (Ptrend¼0.004); this interaction was con-
sidered suggestive only, because several genetic models were
tested (Table 3). However, analysis of the interaction between
inferred haplotypes at IRF5 and class I molecules provided
supportive evidence for the interaction. A model considering
dominance of IRF5 over other factors suggested that IRF5 has
an impact on HLA-C and G genotype distributions. Backward
model selection indicated that HLA-E did not have such
interaction. Individuals who were positive for HLA-Cw6 were
also four times less likely to carry TTAC haplotypes
(OR¼0.27, 95% CI¼ 0.11–0.63, P¼0.003). For individuals
heterozygous for HLA-G insertion/deletion (rs16375), there
was a three times increased frequency of IRF5 GTAT-inferred
haplotypes (OR¼3.79, 95% CI¼ 1.27–11.24, P¼0.016).
Heterozygotes at HLA-G rs16375 also had five times
increased frequency of TTAC-estimated IRF5 haplo-
types (OR¼ 5.09, 95% CI¼1.67–15.5, P¼0.004). Individuals
homozygous for rs16375 deletion/deletion who were carrying
the IRF5 TTAC haplotype, were 4.44 times more common
among patients (95% CI¼ 1.42–13.88, P¼ 0.01) (Table 4).
Because this logistic model is based on haplotype inference
and such estimation can lead to inflated type I error rates,
we explored the interaction between HLA-G and IRF5 by the
non-parametric multifactor dimensionality reduction (MDR)
method and found evidence of interaction between HLA-G
and rs2004640 on IRF5. In a two-locus model shown in
Figure 1, the dark gray background on the squares represents
increased the likelihood to classify study subjects as cases.
The consistency in the classification strategy reached 10 out of
10 sample subsets, meaning that most individuals were
correctly classified into case or control classes in 9 of 10
training sets and also in the testing set. The training OR was
1.7, while the testing OR was 1.4 and the precision was 0.59
(P¼0.01).
Table 1. Characteristics of the study population
Variable % Range First quartile Mean Third quartile SD
Onset before 40 years of age 48.6
Females among controls 60
Females among cases 57
Age of controls 15–87 33 45.4 58 16.2
Age of cases 15–89 30 44.5 58 16.8
Age of onset in years — 12–84 27 41.1 55 17
PASI — 0–47.4 1.5 3.99 4.7 4.8
PASI, psoriasis area and severity index; SD, standard deviation.
PASI, 16.25401.
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A three-locus model also showed interaction between the
loci HLA-G_rs16375, IRF5_rs2004640, and IRF5_rs10954213.
There was a varying pattern of risk at different dimensions of
the combined data, indicating epistasis (data not shown)
(Ritchie et al., 2001).
DISCUSSION
Psoriasis is a condition characterized by an unresolved chronic
state of inflammation, which results from a combination of
predisposing genes and environmental factors (Punchard et al.,
2004).
It was suggested that the inflammatory processes of several
diseases, including psoriasis and SLE, share a common
genetic background. Several loci throughout the genome
are possible candidate control switches for inflammation
(Becker, 2001; Rioux and Abbas, 2005).
IFNs, which are regulated by IRFs, are key modulators of
inflammation in SLE as well as in psoriasis. Genetic variations
in IRF5 associate with SLE by several possible mechanisms,
but most likely by inducing overexpression of the IRF5
protein and consequently altering IFN expression (Graham
et al., 2006; Honda and Taniguchi, 2006). Recently we have
shown that the 50-untranslated region SNP rs2004640 has a
weak functional impact on IRF5 expression, but a strong
genetic association with SLE. In contrast, rs10954213 appears
to have a strong impact on gene expression, but a weak
genetic association with SLE (Kozyrev et al., 2007). At present
we are testing the hypothesis that rs10954213 might be the
SNP with the strongest functional influence on IRF5 levels
and consequently the expression of IRF5’s downstream
targets overshadowing the functional effects, albeit subtle of
the other functional variants. Alternatively, we have not
identified all functional variation in IRF5.
Because the IRF5 association has been the strongest non-
MHC association reported for SLE so far, and because a- and
g-IFNs contribute to the inflammatory process of psoriasis, we
tested the association between IRF5 and psoriasis. We found
that in the Stockholm Psoriasis Cohort there is no evidence
for association to the specific SNPs tested in this study.
Although it is still possible that other variation in this gene
contributes to regulating inflammation in psoriasis, our results
suggest that the genetic networks regulating different types of
inflammation might overlap only partially and IRF5 would
therefore be more specific for SLE.
The IRF family of transcription factors consists of 10
proteins encoded in the human genome along with a number
of heterologous proteins, mostly viral, which regulate
immunity through IFNs. These proteins can promote or
suppress inflammation as homo- or heterodimers (Honda and
Taniguchi, 2006). Previously it was found that polymorph-
isms in IRF2, which map to the psoriasis susceptibility region
3 on chromosome 4, associate with type I (early onset)
psoriasis. An SNP on exon 9 of this gene, which obliterates an
exon splice enhancer, occurs in the homozygote state more
often among psoriasis patients (Foerster et al., 2004). Also,
IRF2-knockout mice express a skin phenotype consisting of
T-cell-associated dermatitis (Honda and Taniguchi, 2006).
Table 2. HLA-Cw6 status and distribution of
genotypes at HLA-G and IRF5 in cases and controls
from the Stockholm psoriasis cohort
Factor Cases % Controls %
HLA-Cw6
N 420 61.40 431 88.87
P 264 38.60 54 11.13
Total 684 485
HLA-G_rs16375
210/210 78 13.20 60 13.54
210/224 290 49.07 199 44.92
224/224 223 37.73 184 41.53
Total 591 443
IRF5_rs2070197
CC 53 9.09 41 9.40
CT 260 44.60 193 44.27
TT 270 46.31 202 46.33
Total 583 436
IRF5_rs2004640
GG 119 20.34 87 20.14
GT 290 49.57 232 53.70
TT 176 30.09 113 26.16
Total 585 432
IRF5_rs10954213
AA 237 41.65 165 38.11
AG 253 44.46 208 48.04
GG 79 13.88 60 13.86
Total 569 433
IRF5_rs2280714
CC 12 2.07 10 2.28
CT 144 24.78 102 23.23
TT 425 73.15 327 74.49
Total 581 439
IRF5, IFN-regulatory factor 5; N, normal; P, psoriatic.
Table 3. Association analysis between psoriasis and
IRF5 rs2070197 adjusted by HLA-G rs16375
HLA-G rs16375 exon
8 deletion/deletion
IRF5_rs2070197 PSO Control OR Lower Upper
T/T-C/T 180 142 1.00 NA NA
C/C 13 22 0.47 0.23 0.96
IRF5, IFN-regulatory factor 5; NA, not available; OR, odds ratio.
P trend, 0.0048715.
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Although there is no evidence of IRF2 and IRF5 dimeriza-
tion so far, this scenario might be a viable way for IFNs’ to
deregulate inflammation in psoriasis.
The most common IRF5 haplotype found in SLE has a
T allele at rs2004640 and a T allele also at rs2280714
(Graham et al., 2006). This SNP, located 5 kb from IRF5, is a
proxy for rs10954213. The SNP rs2070197 was included in
the analyses of IRF5 in psoriasis susceptibility because it
increases the information content of the haplotype (data not
shown) (Kozyrev et al., 2007). The SNP rs10954213 maps to
the 30-untranslated region of IRF5, where its A allele alters
the polyadenylation site, contributing to a shorter and
more stable mRNA, and therefore inducing a higher IRF5
expression (Graham et al., 2006; Kozyrev et al., 2007).
The frequency of the haplotype TCAT (rs2004640–
rs2070197–rs10954213–rs2280714) in SLE was 15% among
European SLE patients (Kozyrev et al., 2007), which is
consistent with the frequency observed in psoriasis. Even
though no evidence of association for this haplotype and
psoriasis was found, we observed that IRF5 haplotypes
containing the rs10954213 A allele had a significant
interaction with the 14-bp deletion in the exon 8 of HLA-G
and also with HLA-Cw6, under a dominant model. It is well
known that HLA-Cw6 has a strong main effect on psoriasis,
but this gene is not likely to act independently of other loci.
Our data shows that IRF5 modifies Cw6-dependent risk in
control individuals. Genotypes carrying Cw6 and the IRF5
TTAC haplotype were more prevalent among controls,
suggesting that this interaction might increase the threshold
pathogenicity of HLA-C in the specific genetic background of
such control individuals.
We also observed an interaction between HLA-G and IRF5,
although these genes did not associate with psoriasis per se.
Interactions without main effects might be the rule for complex
biological systems (Cordell, 2002; Culverhouse et al., 2002),
although it is difficult to establish the frequency of this
phenomenon because researchers seldom test for epistasis.
Several studies have shown that high-order interactions
between loci can be found in genetic analyses despite lack of
main effects (Moore, 2003). However, only through functional
Table 4. Haplotype analysis of IRF5 SNPs using MHC class I molecules as co-factors in a dominant model of
psoriasis susceptibility (effect by heterozygote or homozygote IRF5 haplotypes)
Cases
(n=836)
Controls
(n=651)
Odds
ratio
Lower 95%
CI
Upper 95%
CI Estimate
Standard
error
Z
score Pr(4|z|)
(Intercept) 1.239 0.654 2.347 0.215 0.326 0.658 0.510
cw6P 339 64 8.921 4.748 16.763 2.188 0.322 6.800 1 1011
HLA.G_rs16375SL 428 289 0.580 0.283 1.188 0.545 0.366 1.489 0.137
HLA.G_rs16375SS 328 274 0.465 0.222 0.975 0.766 0.378 2.028 0.043
At least one TGAT haplotype 256 201 0.392 0.144 1.066 0.935 0.510 1.834 0.067
At least one TTAC haplotype 156 102 0.391 0.142 1.078 0.940 0.518 1.815 0.070
At least one TTAT haplotype 345 238 0.711 0.315 1.606 0.341 0.416 0.821 0.412
cw6P: at least one TGAT haplotype 100 20 0.545 0.230 1.294 0.607 0.441 1.375 0.169
cw6P: at least one TTAC haplotype 54 15 0.271 0.116 0.634 1.306 0.434 3.010 0.003
cw6P: at least one TTAT haplotype 142 22 1.458 0.630 3.375 0.377 0.428 0.881 0.379
HLA.G_rs16375SL: at least one TGAT
haplotype
124 86 3.790 1.277 11.242 1.332 0.555 2.401 0.016
HLA.G_rs16375SS: at least one TGAT
haplotype
98 86 2.500 0.830 7.533 0.916 0.563 1.628 0.104
HLA.G_rs16375SL: at least one TTAC
haplotype
88 47 5.096 1.675 15.502 1.628 0.568 2.869 0.004
HLA.G_rs16375SS: at least one TTAC
haplotype
58 38 4.443 1.422 13.883 1.491 0.581 2.566 0.010
HLA.G_rs16375SL: at least one TTAT
haplotype
164 11 1.457 0.587 3.618 0.376 0.464 0.811 0.417
HLA.G_rs16375SS: at least one TTAT
haplotype
139 94 2.257 0.893 5.706 0.814 0.473 1.720 0.085
CI, confidence interval; IRF5, IFN-regulatory factor 5; MHC, major histocompatibility complex; OR, odds ratio; Pr(4|z|), P-value of Z; SNP, single-
nucleotide polymorphism.
Haplotype data Haplotypes were inferred by Hapassoc, which includes in the computation dummy individuals for uncertain haplotypes (Burkett et al.,
2006). This model was called with the formula: catB(cw6+HLAGrs16375)*(I(hGTAT=1)+I(hTTAC=1)+I(hTTAT=1)), where individuals were included if they
had one copy of the inferred haplotype indicated, corresponding to a dominant model. Values of n in this table include dummy individuals included by the
Hapassoc algorithm in order to estimate effect sizes and probabilities for individuals heterozygous genotypes at HLA-G and at IRF5.
Bold values signifies po0.05.
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analyses of the above-mentioned genotypic combinations, one
might be able to reveal their functional implications.
HLA-C and HLA-G were earlier found to have altered
expression in psoriasis, but it is still unclear how these genes
are regulated in psoriasis (Aractingi et al., 2001; Carlen et al.,
2007). In skin biopsies from our collection we recently found
that HLA-C expression was lower in psoriasis than in normal
skin (Carlen et al., 2007). Studying the functional role of IRF5
on HLA-C and G expression may help elucidate the
pathogenic role of these molecules in psoriasis.
We are still far from separating the genotypes (combina-
tion of alleles at different loci) that will permit psoriasis
development and modulate its phenotypic expression. Such
analysis will require an exhaustive survey of alleles, interac-
tion analyses at higher dimensionality, and prohibitive,
perhaps unreachable, sample sizes. However, studying the
interaction between known susceptibility loci and genes in
their functional networks or implicated in inflammation are a
first step toward understanding their pathogenic relationship.
In conclusion, based on the analysis of individual SNPs or
haplotypes at IRF5, there is insufficient evidence to implicate
IRF5 per se as a major player in the inflammatory process of
psoriasis. However, IRF5 might indeed indirectly regulate
class I MHC expression through IFNs and therefore explora-
tion of a potential role of IRF5 in regulating expression of
class I molecules in psoriasis is warranted.
MATERIALS AND METHODS
Patients and controls
The Stockholm Psoriasis Cohort is a prospective collection of
samples and clinical and environmental data from psoriasis patients
and population-matched controls (selected randomly from Swedish
national registries according to sex, age, and place of residence).
This included 645 patients and 472 controls. The patients were
recruited within 1 year of disease onset. Each patient was thoroughly
examined by a dermatologist and whenever psoriasis arthropathy
was suspected, a rheumatologist assessed clinical features to ensure
diagnosis. This study was conducted in accordance to the Declara-
tion of Helsinki Principles. Permission to approach patients and
controls was granted by the local ethics authority, and written
consent was given by all study subjects.
Genotyping
Genomic DNA was extracted from all individuals following standard
conditions (Sambrook et al., 1989). Genotyping was performed using
the Taqman platform 7900HT sequence detection system of Applied
Biosystems (ABI, Foster City, CA). The same company designed and
delivered every SNP assay used in this study. The description of
genotyped markers was published previously (Graham et al., 2006;
Kozyrev et al., 2007).
Statistical analyses
Genotype distributions at IRF5 were tested for Hardy–Weinberg
equilibrium and degree of linkage disequilibrium using Haploview.
Allele, genotype, and haplotype distributions were compared
between cases and controls using the package SNPassoc (Gonza´lez
et al., 2007). Differences were expressed in terms of ORs with their
respective 95% CIs. Logistic regression models were fitted to the data
using Hapassoc, taking into account genotypes at the HLA-C, E, and
G loci as covariates. This software accounts for uncertainty of
haplotype phase determination by an iterative EM algorithm based
on the method of weights (Burkett et al., 2006). Backward model
selection was performed according to ranking of likelihood ratios.
The basis for this choice was that since IRF5 haplotypes correlate
with varying levels of IRF5 transcripts (Graham et al., 2006), they
may affect IFN production, which in turn is important for class I
MHC expression. No forward selection was used because it usually
focuses on finding main effects, which then may be tested for
epistasis, neglecting the potential interactions between loci with
small or no main effects. Since logistic regression modeling can lead
to estimates that have large standard errors, and because the large
number of models tested under multiplicative interactions might
lead to higher type I error rates (Moore, 2003), we complemented
these analyses with the MDR (Hahn et al., 2003). In MDR the data
set is randomly divided into 10 parts. Nine parts are used as training
sets, where the number of specific genotype combinations are
compared between cases and controls, and classified as deviations
from the expected OR under the null hypothesis. Models with
n-loci combinations can be tested, but we tested two loci
combinations between HLA-G and IRF5, as hinted by the logistic
regression method. The remaining part of the sample is reserved for
goodness-of-fit testing. Ten rounds of random partitioning are
performed to ensure usage of the entire sample. A misclassification
measure (mean prediction error¼ number of individuals incorrectly
assigned to a class) and a consistency measure (cross-validation
consistency¼ number of times a combination of loci is identified at
every round of testing) are generated by the MDR software.
A thousand permutations of the analysis were performed in order
to obtain such measures.
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Figure 1. Summary of two-locus genotype combinations between
HLA-G_rs16375 and IRF5_rs2004640 associated with high risk (quadrants
with dark gray background) and low risk. The bar on the left represents the
proportion of cases and the bar on the right the proportion of controls. The
number of individuals with the corresponding genotype combination in
the class case or control appears above each bar. This figure corresponds to
the MDR model with the highest consistency and lower misclassification rate
(CV consistency¼10 of 10; training accuracy¼ 0.57, training OR¼ 1.75,
95% CI¼ 1.3–2.36; testing OR¼ 1.4393, 95% CI¼ 0.58–3.53).
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Correction for multiple testing was performed by Bonferroni’s
method when necessary. Test probabilities below a¼ 0.05 after
correction were considered significant. The R language for statistical
analysis was used as the analytical software platform (Ihaka and
Gentleman, 1996).
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